Avecure Flexible Microwave Ablation Probe For Lung Nodules

Description

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Conditions

Stage I - II Primary Lung Cancer, Stage I Lung Cancer, Stage II Lung Cancer, Lung Cancer Stage I, Lung Cancer Stage II, Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size. This research study involves microwave ablation (MWA)

Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule

Avecure Flexible Microwave Ablation Probe For Lung Nodules

Condition
Stage I - II Primary Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Boston

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.
  • * Pathological proof of target nodule/tumor type and malignancy with specimen considered adequate per institutional laboratory standards
  • * Target nodule/tumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively
  • * Resection/surgical candidate (lobectomy or greater)
  • * Participants must be at least 22 years old and able to provide consent
  • * Subjects in whom flexible bronchoscopy is contraindicated
  • * Target nodule \< 1.0 cm
  • * Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor
  • * Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives
  • * Pacemaker, implantable cardioverter, or another electronic implantable device
  • * Patient cannot tolerate bronchoscopy
  • * Patients with coagulopathy
  • * Patients in other therapeutic lung cancer studies
  • * Subject is pregnant or breastfeeding
  • * COVID-19 positive patient at the time of procedure.

Ages Eligible for Study

22 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Beth Israel Deaconess Medical Center,

Jason Beattie, MD, PRINCIPAL_INVESTIGATOR, Beth Israel Deaconess Medical Center

Study Record Dates

2025-06-30